Business Context and Reporting Period
Company: Alto Neuroscience, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 24, 2024
Event: Entry into a Material Definitive Agreement with The Wellcome Trust Limited to fund the Phase 2b clinical trial of ALTO-100 for bipolar depression.
Key Financial Metrics
This filing does not contain standard financial statements (revenue, profit, cash flow, or margins) as it reports a specific corporate event rather than periodic financial results.
- Debt/Liquidity Event: Entered into an unsecured convertible loan agreement for up to approximately $11.7 million.
- Immediate Funding: $2.0 million received upon execution of the agreement.
- Remaining Funding: Approximately $9.7 million payable in tranches upon completion of clinical trial milestones.
- Interest Rate: Sterling Overnight Index Rate (SONIA) plus 2% (subject to a 9% cap).
- Use of Proceeds: Solely for advancing the development of ALTO-100 in bipolar depression.
Material Changes and Agreement Terms
The primary material change is the creation of a direct financial obligation and potential equity dilution through the convertible loan.
- Conversion Rights: Wellcome may convert the loan into common stock after the second anniversary of the Effective Date or upon a "Sale" of the Company.
- Conversion Price: 20% discount to the 30-day volume-weighted average price (VWAP) of common stock on the NYSE at the time of conversion.
- Dilution Cap: Conversion is limited to 5,363,326 shares, representing 19.9% of shares outstanding as of the agreement date.
- Repayment: Wellcome may require full repayment of the loan plus accrued interest after the fifth anniversary or upon a Sale, unless converted.
- Default: In the event of default, Wellcome may elect to convert the loan or demand full repayment.
Outlook, Risks, and Contingencies
Management Obligations: The Company must use reasonable efforts to conduct the clinical trial, achieve patient recruitment milestones, and further develop ALTO-100. The agreement includes provisions for equitable access to healthcare interventions.
Contingencies:
- Exploitation Rights: If the Company fails to exploit or develop ALTO-100 within a specified period after the trial (excluding safety/efficacy concerns), Wellcome gains a limited right to exploit the drug in bipolar depression, subject to a revenue share.
- Unregistered Securities: Shares issuable upon conversion are unregistered and will rely on Section 4(a)(2) and/or Rule 506 exemptions.
Investor Verification Checklist
- Verify the specific milestones required to trigger the remaining $9.7 million in funding tranches.
- Confirm the current share count to validate the 19.9% dilution cap (5,363,326 shares).
- Review the full text of the Convertible Loan Agreement (Exhibit 10.1) for detailed default conditions and audit rights.
- Monitor the progress of the Phase 2b clinical trial for ALTO-100 in bipolar depression.
- Assess the impact of the 20% discount conversion price on potential future equity dilution.